Ottimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-PD-1/VEGFR2 Antibody
Ottimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-PD-1/VEGFR2 Antibody GlobeNewswire January 07, 2026 First patient dosed and study open in leading oncology centers in US and Australia Phase I/IIA adaptive study aims to assess and optimize the dose of OTP-01 and provide safety, tolerability, and […]